Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michael Scherz"'
Autor:
Lorenzo Di Cesare Mannelli, Mario Maresca, Michael Scherz, Carla Ghelardini, Carlo Farina, Laura Micheli
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:1091-1103
The FOLFOX family of chemotherapy regimens are hampered by the development of a painful neuropathy. Current clinical treatments are inadequate, and furthermore, the research of innovative drugs is strongly disadvantaged by the absence of a preclinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50201445ca8a9d0c9cec5b617533336f
https://doi.org/10.1007/s00280-017-3449-8
https://doi.org/10.1007/s00280-017-3449-8
Publikováno v:
NeuroToxicology. 50:101-107
Background Sorafenib is a kinase inhibitor anticancer drug whose repeated administration causes the onset of a peripheral painful neuropathy. Notably, the efficacy of common analgesic drugs is not adequate and this often leads pre-mature discontinuat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52703f04ade0c7f250110771c2da86ae
https://doi.org/10.1016/j.neuro.2015.08.002
https://doi.org/10.1016/j.neuro.2015.08.002
Publikováno v:
The Journal of Clinical Pharmacology. 55:688-697
Ponesimod is a selective S1P1 receptor modulator, and induces dose-dependent reduction of circulating lymphocytes upon oral dosing. Previous studies showed that single doses up to 75 mg or multiple doses up to 40 mg once daily are well tolerated, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fa0e0a0fc4fd5a468bcd1563f69fb7d
https://doi.org/10.1002/jcph.467
https://doi.org/10.1002/jcph.467
Publikováno v:
The Journal of Clinical Pharmacology. 54:179-188
This multiple-ascending-dose study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator and a potential new treatment for autoimmune diseases. In part A, 10 healthy male and female sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a306e94b0e0845ad6d9d8e9b67dea81
https://doi.org/10.1002/jcph.244
https://doi.org/10.1002/jcph.244
Autor:
Patrick Hess, Gunther Schmidt, Katalin Menyhart, Daniel S. Strasser, Alexander Treiber, Claus Müller, Beat Steiner, Daniel Bur, Christopher Kohl, Roberto Bravo, Christoph Binkert, John Gatfield, Stephan Buchmann, Michael Scherz, Boris Mathys, Virginie Sippel, Stefan Abele, Martin Bolli, Oliver Nayler, Thomas Weller, Céline Mangold
Publikováno v:
Journal of Medicinal Chemistry. 53:4198-4211
Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P conveys its activity through five specific G-protein coupled receptors numbered S1P(1) through S1P(5). Agonists of the S1P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::888f9c30b8d930c09dc96515275dfc76
https://doi.org/10.1021/jm100181s
https://doi.org/10.1021/jm100181s
Autor:
Thomas Weller, Hamed Aissaoui, Francois Jenck, Patrick Hess, Susan Flores, Ralf Koberstein, Petra Hoever, Catherine Brisbare-Roch, Jasper Dingemanse, Michael Scherz, Joop M. A. van Gerven, Oliver Nayler, Sanne de Haas, Stephan Buchmann, Walter Fischli, Martine Clozel, Changbin Qiu, Celia Mueller
Publikováno v:
Nature Medicine. 13:150-155
Orexins are hypothalamic peptides that play an important role in maintaining wakefulness in mammals. Permanent deficit in orexinergic function is a pathophysiological hallmark of rodent, canine and human narcolepsy. Here we report that in rats, dogs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d0f77b48bbd6b76562acdaba22e991
https://doi.org/10.1038/nm1544
https://doi.org/10.1038/nm1544
Autor:
Martine Clozel, Celine Boukhadra, Shuang-Shuang Ding, Michael Scherz, Keith Morrison, Oliver Nayler, Claus Müller, Christophe Binkert, Thomas Weller, Patrick Hess, Jian-Fei Xi, Celia Muller, Magdalena Birker-Robaczewska, Boris Mathys, Walter Fischli, Changbin Qiu, Patrick Ziltener, Markus Rey, Jörg Velker
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 311:204-212
Urotensin-II (U-II) is a cyclic peptide now described as the most potent vasoconstrictor known. U-II binds to a specific G protein-coupled receptor, formerly the orphan receptor GPR14, now renamed urotensin receptor (UT receptor), and present in mamm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad49412c506b54fde1b0a6ebb5bb3be4
https://doi.org/10.1124/jpet.104.068320
https://doi.org/10.1124/jpet.104.068320
Publikováno v:
Journal of Receptors and Signal Transduction. 22:155-168
Urotensin-II (U-II), a vasoactive cyclic neuropeptide, was recently identified as the natural ligand for the G-protein coupled receptor GPR14. The expression pattern of U-II and GPR14 are consistent with a role as a neurohormonal regulatory system in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb885f62a39ad18247be862badda37f
https://doi.org/10.1081/rrs-120014593
https://doi.org/10.1081/rrs-120014593
Autor:
Solange Meyer, Beat Steiner, Martin Bolli, Magdalena Birker, David Lehmann, Michael Scherz, Jörg Velker, Ruben de Kanter, Claus Müller, Patrick Hess, Markus Rey, Roberto Bravo, Boris Mathys, Christopher Kohl, Oliver Nayler, Daniel Bur
Publikováno v:
Journal of medicinal chemistry. 57(1)
Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P1 receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene head.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06de7a43cbf3545aeddc6cc6f7e65b53
https://pubmed.ncbi.nlm.nih.gov/24345087
https://pubmed.ncbi.nlm.nih.gov/24345087
Publikováno v:
Journal of Clinical Oncology. 33:e20650-e20650
e20650 Background: Painful neuropathy is a common adverse event associated with oxaliplatin treatment. It can occur within the first days and may persist from months to years beyond chemotherapy co...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc16faf7cc59d0a92fded57aed15dc1d
https://doi.org/10.1200/jco.2015.33.15_suppl.e20650
https://doi.org/10.1200/jco.2015.33.15_suppl.e20650